Premium
Combined thalidomide and interferon‐α for chronic hepatitis C‐related hepatocellular carcinoma
Author(s) -
WANG TsangEn,
LIM KenHong,
HUANG MingJer
Publication year - 2007
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2006.00082.x
Subject(s) - thalidomide , medicine , hepatocellular carcinoma , interferon , chronic hepatitis , gastroenterology , combination therapy , hepatitis , carcinoma , oncology , immunology , virus , multiple myeloma
Successful treatment with the combination of low dose thalidomide and interferon‐α is described in an 89‐year‐old man who had chronic hepatitis C‐related metastatic hepatocellular carcinoma. Thalidomide 100 mg/day and interferon‐α2b 3 million units/week were prescribed. After 9 months of the combination therapy, his serum α‐fetoprotein level had declined from 24 549 ng/mL to less than 2.76 ng/mL. The recurrent liver tumors decreased in size and the metastatic lung lesions had complete remission after treatment. Combination therapy with lower dose interferon‐α and thalidomide, two antiangiogenic drugs with different mechanisms of action, was associated with a good response and was well tolerated in this preliminary study.